OncologyOnline.net

Oncology Xagena

Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF list as 3rd line chemotherapy for patients with locally advanced or metastatic breast c ...


The application was for Regorafenib ( Stivarga ) to remain in the Cancer Drugs Fund ( CDF ) as treatment for patients with non-resectable or metastatic gastrointestinal stromal tumours ( GISTs ) who w ...


The LUME-Lung 1 trial has demonstrated a significant overall survival advantage for Nintedanib ( Vargatef ) plus Docetaxel ( Taxotere ) compared with placebo plus Docetaxel as second-line therapy for ...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung 3 and LUX-Lung 6, in patients with EGFR-mutant advanced non ...


The Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to enter the CDF as an option for patients with locally advanced or metastatic HER-2 negative breast can ...


Basal cell carcinomas are the most common skin cancers. They are usually localised and carry a good prognosis. There is no standard treatment for the rare patients with metastatic basal cell carcinoma ...


The efficacy and safety of Dabigatran ( Pradaxa ) for treatment of venous thromboembolism ( VTE ) were demonstrated in two trials. It is unclear if the results pertain to patients with cancer and veno ...


The FDA ( Food and Drug Administration ) has granted Priority Review for the New Drug Application ( NDA ) for Cobimetinib in combination with Vemurafenib ( Zelboraf ) for the treatment of people with ...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) squamous non-small cell lung cancer ( NSCLC ) with progres ...


LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive care in comparison with placebo and best supportive care, as a third-line or fourth-line the ...


Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program ( EAP ) provided an opportunity to evaluate the f ...


Although anti–CTLA-4 and anti–PD-1 monoclonal antibodies ( mAbs ) may overcome T-cell suppression, T-cell activation depends on the engagement of the antigen receptor and the activating costimulation ...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial has assessed the antitumor acti ...